A Photolabile Curcumin‐Diazirine Analogue Enables Phototherapy with Physically and Molecularly Produced Light for Alzheimer's Disease Treatment**

Author:

Kuang Shi1ORCID,Zhu Biyue1,Zhang Jing1,Yang Fan1,Wu Bo1,Ding Weihua2,Yang Liuyue2,Shen Shiqian2,Liang Seven H.3,Mondal Prasenjit4,Kumar Mohanraja5,Tanzi Rudolph E.4,Zhang Can4,Chao Hui6,Ran Chongzhao1ORCID

Affiliation:

1. Athinoula A. Martinos Center for Biomedical Imaging Department of Radiology Massachusetts General Hospital Harvard Medical School Building 149, Charlestown Boston MA-02129 USA

2. MGH Center for Translational Pain Research Department of Anesthesia Critical Care and Pain Medicine Massachusetts General Hospital Harvard Medical School Boston MA-02129 USA

3. Department of Radiology Massachusetts General Hospital Harvard Medical School Boston MA-02114 USA

4. Genetics and Aging Research Unit McCance Center for Brain Health MassGeneral Institute for Neurodegenerative Disease Department of Neurology Massachusetts General Hospital Harvard Medical School Boston MA-02129 USA

5. Department of Chemistry Massachusetts Institute of Technology Cambridge MA-02139 USA

6. MOE Key Laboratory of Bioinorganic and Synthetic Chemistry School of Chemistry Sun Yat-Sen University Guangzhou 510006 P. R. China

Abstract

AbstractThe development of Alzheimer's disease (AD) drugs has recently witnessed substantial achievement. To further enhance the pool of drug candidates, it is crucial to explore non‐traditional therapeutic avenues. In this study, we present the use of a photolabile curcumin‐diazirine analogue, CRANAD‐147, to induce changes in properties, structures (sequences), and neurotoxicity of amyloid beta (Aβ) species both in cells and in vivo. This manipulation was achieved through irradiation with LED light or molecularly generated light, dubbed as “molecular light”, emitted by the chemiluminescence probe ADLumin‐4. Next, aided by molecular chemiluminescence imaging, we demonstrated that the combination of CRANAD‐147/LED or CRANAD‐147/ADLumin‐4 (molecular light) could effectively slow down the accumulation of Aβs in transgenic 5xFAD mice in vivo. Leveraging the remarkable tissue penetration capacity of molecular light, phototherapy employing the synergistic effect of a photolabile Aβ ligand and molecular light emerges as a promising alternative to conventional AD treatment interventions.

Funder

Foundation for the National Institutes of Health

Publisher

Wiley

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3